PPARγ agonists and coronary atherosclerosis

Melanie S. Sulistio, Adrienne Zion, Nandish Thukral, Robert J Chilton

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States. The key relationship between these two diseases (knowing that T2DM is a strong risk factor for cardiovascular disease) is insulin resistance and the detrimental effect it has on macrovasculature. Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor γ agonists that are beneficial in the treatment of T2DM and have the added benefit of modifying lipid profiles. This review discusses the basic science linking insulin resistance to atherosclerosis and describes the major TZD trials in the recent literature. It also addresses the clinical implications of these studies and media scrutiny surrounding the recent controversial report that TZDs may be linked to an increased risk of myocardial infarction.

Original languageEnglish (US)
Pages (from-to)134-141
Number of pages8
JournalCurrent Atherosclerosis Reports
Volume10
Issue number2
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Thiazolidinediones
Peroxisome Proliferator-Activated Receptors
Type 2 Diabetes Mellitus
Coronary Artery Disease
Insulin Resistance
Cardiovascular Diseases
Cause of Death
Atherosclerosis
Myocardial Infarction
Lipids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sulistio, M. S., Zion, A., Thukral, N., & Chilton, R. J. (2008). PPARγ agonists and coronary atherosclerosis. Current Atherosclerosis Reports, 10(2), 134-141. https://doi.org/10.1007/s11883-008-0020-4

PPARγ agonists and coronary atherosclerosis. / Sulistio, Melanie S.; Zion, Adrienne; Thukral, Nandish; Chilton, Robert J.

In: Current Atherosclerosis Reports, Vol. 10, No. 2, 04.2008, p. 134-141.

Research output: Contribution to journalArticle

Sulistio, MS, Zion, A, Thukral, N & Chilton, RJ 2008, 'PPARγ agonists and coronary atherosclerosis', Current Atherosclerosis Reports, vol. 10, no. 2, pp. 134-141. https://doi.org/10.1007/s11883-008-0020-4
Sulistio, Melanie S. ; Zion, Adrienne ; Thukral, Nandish ; Chilton, Robert J. / PPARγ agonists and coronary atherosclerosis. In: Current Atherosclerosis Reports. 2008 ; Vol. 10, No. 2. pp. 134-141.
@article{5698376e925e4e0e86a0602ff5501eeb,
title = "PPARγ agonists and coronary atherosclerosis",
abstract = "The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States. The key relationship between these two diseases (knowing that T2DM is a strong risk factor for cardiovascular disease) is insulin resistance and the detrimental effect it has on macrovasculature. Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor γ agonists that are beneficial in the treatment of T2DM and have the added benefit of modifying lipid profiles. This review discusses the basic science linking insulin resistance to atherosclerosis and describes the major TZD trials in the recent literature. It also addresses the clinical implications of these studies and media scrutiny surrounding the recent controversial report that TZDs may be linked to an increased risk of myocardial infarction.",
author = "Sulistio, {Melanie S.} and Adrienne Zion and Nandish Thukral and Chilton, {Robert J}",
year = "2008",
month = "4",
doi = "10.1007/s11883-008-0020-4",
language = "English (US)",
volume = "10",
pages = "134--141",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "2",

}

TY - JOUR

T1 - PPARγ agonists and coronary atherosclerosis

AU - Sulistio, Melanie S.

AU - Zion, Adrienne

AU - Thukral, Nandish

AU - Chilton, Robert J

PY - 2008/4

Y1 - 2008/4

N2 - The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States. The key relationship between these two diseases (knowing that T2DM is a strong risk factor for cardiovascular disease) is insulin resistance and the detrimental effect it has on macrovasculature. Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor γ agonists that are beneficial in the treatment of T2DM and have the added benefit of modifying lipid profiles. This review discusses the basic science linking insulin resistance to atherosclerosis and describes the major TZD trials in the recent literature. It also addresses the clinical implications of these studies and media scrutiny surrounding the recent controversial report that TZDs may be linked to an increased risk of myocardial infarction.

AB - The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States. The key relationship between these two diseases (knowing that T2DM is a strong risk factor for cardiovascular disease) is insulin resistance and the detrimental effect it has on macrovasculature. Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor γ agonists that are beneficial in the treatment of T2DM and have the added benefit of modifying lipid profiles. This review discusses the basic science linking insulin resistance to atherosclerosis and describes the major TZD trials in the recent literature. It also addresses the clinical implications of these studies and media scrutiny surrounding the recent controversial report that TZDs may be linked to an increased risk of myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=41749118732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749118732&partnerID=8YFLogxK

U2 - 10.1007/s11883-008-0020-4

DO - 10.1007/s11883-008-0020-4

M3 - Article

C2 - 18417068

AN - SCOPUS:41749118732

VL - 10

SP - 134

EP - 141

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 2

ER -